HRP20181245T1 - Anti-cd38 protutijela - Google Patents
Anti-cd38 protutijelaInfo
- Publication number
- HRP20181245T1 HRP20181245T1 HRP20181245TT HRP20181245T HRP20181245T1 HR P20181245 T1 HRP20181245 T1 HR P20181245T1 HR P20181245T T HRP20181245T T HR P20181245TT HR P20181245 T HRP20181245 T HR P20181245T HR P20181245 T1 HRP20181245 T1 HR P20181245T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061428699P | 2010-12-30 | 2010-12-30 | |
| US201161470406P | 2011-03-31 | 2011-03-31 | |
| US201161470382P | 2011-03-31 | 2011-03-31 | |
| US201161485104P | 2011-05-11 | 2011-05-11 | |
| EP11811633.4A EP2658871B1 (en) | 2010-12-30 | 2011-12-30 | Anti-cd38 antibodies |
| PCT/US2011/068235 WO2012092612A1 (en) | 2010-12-30 | 2011-12-30 | Anti-cd38 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20181245T1 true HRP20181245T1 (hr) | 2018-10-05 |
Family
ID=45498158
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181245TT HRP20181245T1 (hr) | 2010-12-30 | 2011-12-30 | Anti-cd38 protutijela |
| HRP20181176TT HRP20181176T1 (hr) | 2010-12-30 | 2011-12-30 | Konjugirana anti-cd38 protutijela |
| HRP20201996TT HRP20201996T1 (hr) | 2010-12-30 | 2020-12-14 | Anti-cd38 protutijela |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181176TT HRP20181176T1 (hr) | 2010-12-30 | 2011-12-30 | Konjugirana anti-cd38 protutijela |
| HRP20201996TT HRP20201996T1 (hr) | 2010-12-30 | 2020-12-14 | Anti-cd38 protutijela |
Country Status (38)
Families Citing this family (194)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8263746B2 (en) | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
| US9200061B2 (en) * | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL goldÂź-derived therapeutic antibodies specific for human CD3i |
| KR20150139636A (ko) | 2005-10-12 | 2015-12-11 | ëȘšë„ŽíŹìì€ ìêČ | ìžê° ïœïœ38ì íčìŽì ìž ìì ìžê° ïœïœïœïœïœ ïœïœïœïœ-ì ë ìčëŁ íìČŽë€ì ìì± ë° íëĄíìŒë§ |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| KR101912957B1 (ko) | 2010-09-27 | 2018-10-29 | ëȘšë„ŽíŹìì€ ìêČ | ë€ë°ì± êłšììą ë° nhl ìčëŁë„Œ ìí í-cd38 íìČŽ ë° ë ë 늏ëë§ìŽë ëë 볎넎í ìĄ°ë° |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | ۧÙŰŁŰŹŰłŰ§Ù Ű§ÙÙ Ű¶Ű§ŰŻŰ© ÙÙ cd38 |
| ES3033729T3 (en) | 2011-10-28 | 2025-08-07 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| US20150157619A1 (en) | 2012-07-10 | 2015-06-11 | Takeda Pharmaceutical Company Limited | Pharmaceutical preparation for injection |
| SG11201502163QA (en) | 2012-09-25 | 2015-04-29 | Morphosys Ag | Combinations and uses thereof |
| US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| UA118255C2 (uk) * | 2012-12-07 | 2018-12-26 | ĐĄĐ°ĐœĐŸŃŃ | ĐĐŸĐŒĐżĐŸĐ·ĐžŃŃŃ, ŃĐșĐ° ĐŒŃŃŃĐžŃŃ Đ°ĐœŃĐžŃŃĐ»ĐŸ ĐŽĐŸ cd38 Ń Đ»Đ”ĐœĐ°Đ»ŃĐŽĐŸĐŒŃĐŽ |
| US9815904B2 (en) | 2013-04-16 | 2017-11-14 | Genetech, Inc. | Pertuzumab variants and evaluation thereof |
| PT3677591T (pt) * | 2013-04-29 | 2023-02-17 | Teva Pharmaceuticals Australia Pty Ltd | Anticorpos anti-cd38 e fusÔes a interferão alfa-2b atenuado |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| EP3063173B1 (en) * | 2013-10-31 | 2020-07-29 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
| EP3176185A1 (en) | 2013-11-04 | 2017-06-07 | Glenmark Pharmaceuticals S.A. | Production of t cell retargeting hetero-dimeric immunoglobulins |
| WO2015123687A1 (en) * | 2014-02-14 | 2015-08-20 | Centrose, Llc | Extracellular targeted drug conjugates |
| US9732154B2 (en) * | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| US9603927B2 (en) * | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| JP2017513818A (ja) | 2014-03-15 | 2017-06-01 | ăăă«ăăŁăč ăąăŒăČăŒ | ăăĄă©æćććźčäœăäœżçšăăçăźćŠçœź |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | йДĐČĐ° ЀаŃĐŒĐ°ŃŃŃŃĐžĐșалз ĐŃŃŃĐ”ĐčĐ»ŃĐ° ĐŃŃ ĐŃĐŽ | ĐĐŸĐŒĐ±ŃĐœĐ°ŃŃŃ Đ»Đ”ĐœĐ°Đ»ŃĐŽĐŸĐŒŃĐŽŃ Đ°Đ±ĐŸ ĐżĐŸĐŒĐ°Đ»ŃĐŽĐŸĐŒŃĐŽŃ Ń ĐșĐŸĐœŃŃŃŃĐșŃŃŃ Đ°ĐœŃĐž-cd38 Đ°ĐœŃĐžŃŃĐ»ĐŸ-Đ°ŃĐ”ĐœŃĐčĐŸĐČĐ°ĐœĐžĐč ŃĐœŃĐ”ŃŃĐ”ŃĐŸĐœ Đ°Đ»ŃŃĐ°-2b ŃĐ° ŃĐżĐŸŃŃб Đ»ŃĐșŃĐČĐ°ĐœĐœŃ ŃŃб'ŃĐșŃĐ°, ŃĐșĐžĐč ĐŒĐ°Ń cd38-Đ”ĐșŃĐżŃĐ”ŃŃŃŃŃ ĐżŃŃ Đ»ĐžĐœŃ |
| AU2015289644A1 (en) | 2014-07-15 | 2017-02-02 | Juno Therapeutics, Inc. | Engineered cells for adoptive cell therapy |
| EP3193915A1 (en) | 2014-07-21 | 2017-07-26 | Novartis AG | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
| PH12017500442B1 (en) | 2014-09-09 | 2023-05-24 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
| PE20170908A1 (es) | 2014-10-29 | 2017-07-12 | Teva Pharmaceuticals Australia Pty Ltd | VARIANTES DE INTERFERON a2b |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimÚres reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| IL307913A (en) * | 2014-12-04 | 2023-12-01 | Janssen Biotech Inc | Anti-CD38 antibodies for the treatment of acute myeloid leukemia |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| MA41555A (fr) * | 2015-02-17 | 2017-12-26 | Millennium Pharm Inc | Polythérapie pour le traitement du cancer |
| EP3280443B1 (en) | 2015-04-08 | 2022-08-24 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd38 |
| EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
| CN108136218B (zh) | 2015-05-20 | 2022-12-13 | è©čæŁźçç©ç§æć Źćž | çšäșæČ»ç蜻éŸæ·çČæ ·ćæ§ćć ¶ćźcd38éłæ§èĄæ¶Čæ¶æ§èżç€çæcd38æäœ |
| MX2017015493A (es) | 2015-05-30 | 2018-02-09 | Molecular Templates Inc | Andamiajes de la subunidad a de la toxina shiga desinmunizados y moleculas con direccion a las celulas que los comprenden. |
| PE20181323A1 (es) * | 2015-06-22 | 2018-08-14 | Janssen Biotech Inc | Terapias de combinacion para enfermedades malignas hematologicas con anticuerpos anti-cd38 e inhibidores de survivina |
| PT3313441T (pt) * | 2015-06-24 | 2024-05-07 | Janssen Biotech Inc | Modulação imunitåria e tratamento de tumores sólidos com anticorpos que se ligam especificamente a cd38 |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| WO2017005734A1 (en) | 2015-07-06 | 2017-01-12 | Ucb Biopharma Sprl | Tau-binding antibodies |
| MA42895A (fr) | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
| WO2017027392A1 (en) | 2015-08-07 | 2017-02-16 | Novartis Ag | Treatment of cancer using chimeric cd3 receptor proteins |
| US20180264038A1 (en) | 2015-09-28 | 2018-09-20 | Regents Of The University Of Minnesota | Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity |
| CN116789841A (zh) | 2015-10-25 | 2023-09-22 | è”èŻșèČ | çšäșéąéČææČ»çhivææçäžçčćŒæ§ć/æäžä»·ç»ćèçœ |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| HUE053366T2 (hu) | 2015-11-03 | 2021-06-28 | Janssen Biotech Inc | SzubkutĂĄn anti-CD38-ellenanyag-kĂ©szĂtmĂ©nyek Ă©s alkalmazĂĄsuk |
| CN116334143A (zh) | 2015-11-23 | 2023-06-27 | èŻșćèĄä»œæéć Źćž | äŒćçæ ąç æŻèœŹç§»èœœäœćć ¶çšé |
| EP4219689A3 (en) | 2015-12-30 | 2023-12-20 | Novartis AG | Immune effector cell therapies with enhanced efficacy |
| AU2017226960B2 (en) * | 2016-03-04 | 2024-03-21 | Morphosys Ag | Clinical assessment of M-protein response in multiple myeloma |
| WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
| PE20190128A1 (es) | 2016-04-13 | 2019-01-17 | Sanofi Sa | Proteinas de union triespecificas y/o trivalentes |
| HUE063824T2 (hu) | 2016-04-13 | 2024-02-28 | Sanofi Sa | Trispecifikus és/vagy trivalens kötÔfehérjék |
| JP7166512B2 (ja) * | 2016-05-03 | 2022-11-08 | ă€ăłăčăăŁăă„ăŒă ăă·ă§ăă« ă ă© ă”ăłă ăš ă ă© ă«ă·ă§ă«ă·ă„ ăĄăăŁă«ă« ïŒă€ăłă»ă«ă ïŒ | ççăźă€ăĄăŒăžăłă°ăźăăăźććæšèăšăăŠăźïŒŁïŒ€ïŒïŒïœïœïœ ïœ |
| EP3474895A1 (en) * | 2016-06-28 | 2019-05-01 | UMC Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
| US11613586B2 (en) | 2016-07-15 | 2023-03-28 | Takeda Pharmaceutical Company Limited | Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies |
| JP7241677B2 (ja) | 2016-07-19 | 2023-03-17 | ăăă»ăăĄăŒăă·ă„ăŒăăŁă«ă«ășă»ăȘăŒăčăă©ăȘăąă»ăăŒăăŁăŻă€ă»ăȘăăăă | æïœïœïŒïŒäœ”çšçæł |
| US10478497B2 (en) | 2016-07-20 | 2019-11-19 | Hybrigenics S.A. | Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer |
| EP4295918A3 (en) | 2016-11-02 | 2024-03-20 | Bristol-Myers Squibb Company | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
| US20210333279A1 (en) * | 2016-11-04 | 2021-10-28 | Aarhus Universitet | Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor |
| WO2018111340A1 (en) | 2016-12-16 | 2018-06-21 | Novartis Ag | Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells |
| EP3574005B1 (en) | 2017-01-26 | 2021-12-15 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
| CN110582509A (zh) | 2017-01-31 | 2019-12-17 | èŻșćèĄä»œæéć Źćž | äœżçšć ·æć€çčćŒæ§çć”ćtç»èćäœèçœæČ»ççç |
| EP3589647A1 (en) | 2017-02-28 | 2020-01-08 | Novartis AG | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
| WO2018159549A1 (ja) * | 2017-03-01 | 2018-09-07 | æ ȘćŒäŒç€Ÿè ćç ç 究æ | èȘć·±ć ç«çŸæŁăźäșéČăăăłïŒăŸăăŻæČ»çć€ă䞊ăłă«ăăŻăŻăăł |
| KR20190133005A (ko) | 2017-03-24 | 2019-11-29 | ì ìŒìż ìœê”ê°ë¶ìí€ê°ìŽì€ | í IgM/B ìžíŹ íë©Ž íì ìŽì€ íčìŽì± íìČŽ |
| US11104737B2 (en) | 2017-03-28 | 2021-08-31 | Rigel Pharmaceuticals, Inc. | ACVR2A-specific antibody and method of treatment of muscle atrophy |
| BR112019021520A2 (pt) | 2017-04-14 | 2020-08-04 | Tollnine, Inc. | oligonucleotĂdeo, composto, polinucleotĂdeo imunomodulador, composição, conjugado, mĂ©todo para modular um receptor, mĂ©todo de tratamento de um tumor, mĂ©todo de tratamento de cĂąncer, mĂ©todo para tratar um tumor, mĂ©todo de prevenção de cĂąncer, mĂ©todo para induzir uma resposta imune |
| AU2018280871B2 (en) * | 2017-06-08 | 2024-09-26 | Black Belt Therapeutics Ltd | CD38 modulating antibody |
| KR20250025513A (ko) * | 2017-06-08 | 2025-02-21 | ëžë ëČšíž í ëŒíší±ì€ 늏믞í°ë | Cd38 ìĄ°ì íìČŽ |
| CA3066547A1 (en) | 2017-06-08 | 2018-12-13 | Black Belt Therapeutics Limited | Cd38 modulating antibody |
| WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
| DK3538645T3 (da) | 2017-06-20 | 2021-04-19 | Inst Curie | Immunceller der mangler suv39h1 |
| EP3641831B1 (en) * | 2017-06-20 | 2024-11-06 | Sorrento Therapeutics, Inc. | Cd38 antibody drug conjugate |
| EP3434692A1 (en) * | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
| US11542338B2 (en) | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CA3072296A1 (en) * | 2017-08-16 | 2019-02-21 | Black Belt Therapeutics Limited | Cd38 antibody |
| CA3073085A1 (en) | 2017-08-16 | 2019-02-21 | Black Belt Therapeutics Limited | Cd38 modulating antibody |
| AU2018331421A1 (en) | 2017-09-13 | 2020-04-30 | Teneobio, Inc. | Heavy chain antibodies binding to ectoenzymes |
| CA3078800A1 (en) | 2017-10-10 | 2019-04-18 | Sanofi | Anti-cd38 antibodies and methods of use |
| KR20200069358A (ko) | 2017-10-25 | 2020-06-16 | ë žíë„Ží°ì€ ìêČ | í€ë©ëŒ íì ìì©ìČŽ ë°í ìžíŹì ì ìĄ° ë°©ëČ |
| US20210040205A1 (en) | 2017-10-25 | 2021-02-11 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
| CN111565751A (zh) | 2017-10-31 | 2020-08-21 | è©čæŁźçç©ç§æć Źćž | æČ»çé«ć±ć€ćæ§éȘšé«ç€çæčæł |
| WO2019089798A1 (en) | 2017-10-31 | 2019-05-09 | Novartis Ag | Anti-car compositions and methods |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| US11564946B2 (en) | 2017-11-01 | 2023-01-31 | Juno Therapeutics, Inc. | Methods associated with tumor burden for assessing response to a cell therapy |
| MA49911A (fr) | 2017-11-01 | 2020-06-24 | Juno Therapeutics Inc | Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
| US20210254000A1 (en) | 2017-11-01 | 2021-08-19 | Juno Therapeutics, Inc. | Process for producing a t cell composition |
| DK3704230T3 (da) | 2017-11-01 | 2025-01-02 | Juno Therapeutics Inc | FremgangsmÄde til generering af terapeutiske sammensÊtninger af modificerede celler |
| BR112020008638A2 (pt) | 2017-11-01 | 2020-10-20 | Juno Therapeutics Inc | receptores de antĂgenos quimĂ©ricos especĂficos para antĂgenos de maturação de cĂ©lulas b (bcma) |
| CA3080109A1 (en) | 2017-11-03 | 2019-05-09 | Sorrento Therapeutics, Inc. | Cd38-directed chimeric antigen receptor constructs |
| MX2020005562A (es) * | 2017-11-30 | 2020-08-20 | Genentech Inc | Anticuerpos anti-pd-l1 y métodos para utilizarlos para la detección de pd-l1. |
| IL274806B2 (en) * | 2017-12-05 | 2025-04-01 | Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct | T cells containing chimeric receptors for CD138 and CD38 antigens and their use |
| JP2021505615A (ja) | 2017-12-08 | 2021-02-18 | ăžă„ăăŒ ă»ă©ăă„ăŒăăŁăŻăč ă€ăłăłăŒăăŹă€ăăă | 现èçæłăăăłéąéŁæčæłăźăăăźèĄšçŸćăăŒă«ăŒ |
| KR102853341B1 (ko) | 2017-12-08 | 2025-09-02 | ìŁŒë ž ìëŹíší°íŹì€ ìžìœíŒë ìŽí°ë | ìĄ°ìë ïœ ìžíŹì ìĄ°ì±ëŹŒì ì ìĄ°íë ë°©ëČ |
| SG11202005228YA (en) | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Serum-free media formulation for culturing cells and methods of use thereof |
| WO2019140410A1 (en) | 2018-01-12 | 2019-07-18 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
| CN110144008B (zh) * | 2018-02-12 | 2021-03-19 | æć·ć°ć„çç©ææŻæéć Źćž | Cd38èçœæäœćć ¶ćșçš |
| BR112020019710A2 (pt) * | 2018-03-28 | 2021-01-26 | Takeda Pharmaceutical Company Limited | mĂ©todos para tratar uma doença em um sujeito e para tratar um cĂąncer hematolĂłgico em um sujeito, e, forma farmacĂȘutica unitĂĄria. |
| CN108318689A (zh) * | 2018-04-09 | 2018-07-24 | ćäșŹć€§ćŠæ·±ćłç 究çéą | äžç§ć€ćæ§éȘšé«ç€çèŻææčæł |
| WO2019210153A1 (en) | 2018-04-27 | 2019-10-31 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| US20210396739A1 (en) | 2018-05-01 | 2021-12-23 | Novartis Ag | Biomarkers for evaluating car-t cells to predict clinical outcome |
| US12048745B2 (en) | 2018-05-01 | 2024-07-30 | Augusta University Research Institute, Inc. | Methods for detecting and reversing immune therapy resistance |
| WO2019227003A1 (en) | 2018-05-25 | 2019-11-28 | Novartis Ag | Combination therapy with chimeric antigen receptor (car) therapies |
| US20210123075A1 (en) | 2018-06-08 | 2021-04-29 | Novartis Ag | Compositions and methods for immunooncology |
| CN108752475B (zh) * | 2018-06-14 | 2021-07-30 | ćäșŹæșä»çŸćçç©ç§ææéć Źćž | æäșșcd38æäœćć ¶çšé |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| MA53123A (fr) | 2018-07-13 | 2021-05-19 | Genmab As | Thérapie à médiation par trogocytose utilisant des anticorps cd38 |
| KR20210031932A (ko) | 2018-07-13 | 2021-03-23 | ì 맔 ììŽ/ìì€ | Cd38 íìČŽì ëłìŽìČŽ ë° ê·žì ì©ë |
| EA202190469A1 (ru) | 2018-08-09 | 2021-06-28 | ĐжŃĐœĐŸ йДŃĐ°ĐżŃŃŃĐžĐșŃ, ĐĐœĐș. | ĐĄĐżĐŸŃĐŸĐ±Ń ĐŸŃĐ”ĐœĐșĐž ĐžĐœŃДгŃĐžŃĐŸĐČĐ°ĐœĐœŃŃ ĐœŃĐșĐ»Đ”ĐžĐœĐŸĐČŃŃ ĐșĐžŃĐ»ĐŸŃ |
| KR20210057752A (ko) | 2018-09-11 | 2021-05-21 | ì§ìì íšê·žëŁšìŽ ë©ëìš ì»ŽíŒë 늏믞í°ë | í-cd38 íìČŽ, ìŽì íì êČ°í© ëšíž, ë° ì ìœ ì©ë |
| CN109053892B (zh) | 2018-09-19 | 2021-03-26 | èć·æćŠç»Žçç©ææŻèĄä»œæéć Źćž | çčćŒç»ćäșșćçŽcd38æćçćć éæäœćć ¶ć¶ć€æčæłäžćșçš |
| TWI856979B (zh) | 2018-10-09 | 2024-10-01 | æłćèłœè«ŸèČć Źćž | äžçčç°æ§æïœïœïŒïŒăæïœïœïŒïŒćæïœïœïŒç”ćèçœćçšæŒæČ»çç æŻææçäœżçšæčæł |
| CN112955467A (zh) | 2018-10-26 | 2021-06-11 | çčć°Œć„„çç©èĄä»œæéć Źćž | äžcd38ç»ćçééŸæäœ |
| TW202021981A (zh) | 2018-11-01 | 2020-06-16 | çŸćć„è«ŸæČ»çæéć Źćž | Gèçœć¶ććé«céĄçŹŹ5矀æćĄdïŒgprc5dïŒçčç°æ§ć”ćæććé« |
| SG11202104188VA (en) | 2018-11-01 | 2021-05-28 | Juno Therapeutics Inc | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| MX2021007047A (es) | 2018-12-14 | 2021-10-26 | Morphosys Ag | Formulaciones de anticuerpos. |
| BR112021011874A2 (pt) | 2018-12-20 | 2021-09-08 | Novartis Ag | Regime de dosagem e combinação farmacĂȘutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona |
| CA3127520A1 (en) * | 2019-01-23 | 2020-07-30 | Encefa | Cd31 competitors and uses thereof |
| EP3914610A1 (en) | 2019-01-23 | 2021-12-01 | Millennium Pharmaceuticals, Inc. | Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors |
| CN113710324B (zh) | 2019-01-23 | 2025-02-14 | ć犧ć¶èŻć Źćž | æcd38æäœ |
| AU2020222346B2 (en) | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| MX2021011181A (es) | 2019-03-15 | 2022-01-19 | Morphosys Ag | Anticuerpos anti-cd38 y sus composiciones farmacéuticas para el tratamiento de la enfermedad autoinmune mediada por autoanticuerpos. |
| US20200308284A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Lenalidomide and Dexamethasone |
| US20200316197A1 (en) * | 2019-03-28 | 2020-10-08 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Bortezomib and Dexamethasone |
| WO2020194245A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically proven subcutaneous pharmaceutical compositions comprising anti-cd38 antibodies and their uses in combination with bortezomib, melphalan and prednisone |
| US20200308296A1 (en) * | 2019-03-28 | 2020-10-01 | Janssen Biotech, Inc. | Clinically Proven Subcutaneous Pharmaceutical Compositions Comprising Anti-CD38 Antibodies and Their Uses in Combination with Pomalidomide and Dexamethasone |
| CN114524877A (zh) * | 2019-03-29 | 2022-05-24 | çŽąäŒŠæèŻäžæéć Źćž | ç»ćcd38çç»ć·„çšæčé çććŒæäœ |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| JP7664175B2 (ja) * | 2019-04-09 | 2025-04-17 | ă”ăă〠| äžéçčç°æ§ç”ćæ§ăżăłăăŻèłȘăæčæłăăăăłăăźäœżçš |
| KR20220016475A (ko) | 2019-05-01 | 2022-02-09 | ìŁŒë ž ìëŹíší°íŹì€ ìžìœíŒë ìŽí°ë | ëłíë ïœïœïœïœïœ2 ì ì ì ìąìì ìŹìĄ°í© ìì©ìČŽë„Œ ë°ííë ìžíŹ, êŽë š íŽëŠŹëŽíŽë ì€í°ë ë° ë°©ëČ |
| EP3962519A1 (en) | 2019-05-01 | 2022-03-09 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods |
| KR102878895B1 (ko) | 2019-05-21 | 2025-10-31 | ë žíë„Ží°ì€ ìêČ | Cd19 êČ°í© ë¶ì ë° ìŽì ì©ë |
| EP3980064A1 (en) * | 2019-06-10 | 2022-04-13 | Takeda Pharmaceutical Company Limited | Combination therapies using cd-38 antibodies |
| KR20220026586A (ko) | 2019-06-27 | 2022-03-04 | íŹëŠŹì€íŒ í ëŒíší±ì€ ìêČ | ì ìčëŁë„Œ ìí í€ë©ëŒ íì ìì©ìČŽ tìžíŹ ë° nkìžíŹ ì”ì ì ì ì©ë |
| WO2021003074A1 (en) * | 2019-07-03 | 2021-01-07 | Crystal Bioscience Inc. | Anti-cd38 antibody and methods of use thereof |
| US20220251572A1 (en) | 2019-07-23 | 2022-08-11 | Mnemo Therapeutics | Immune cells defective for suv39h1 |
| CN112538114B (zh) * | 2019-09-20 | 2025-05-02 | äžæ”·æźéçç©ç§ææéć Źćž | æäșșcd38æäœćć ¶ćșçš |
| US20220387317A1 (en) * | 2019-11-07 | 2022-12-08 | Ohio State Innovation Foundation | Methods and compositions relating to selective intracellular delivery of cd38 inhibitors |
| CN112876563B (zh) * | 2019-11-29 | 2022-08-16 | ćș·èŻșäșçç©ć»èŻç§æïŒæéœïŒæéć Źćž | èŻç©ç»ćç©ćć ¶ć¶ć€æčæłććșçš |
| JP2023507120A (ja) | 2019-12-18 | 2023-02-21 | ăăăȘăă©ăŒïŒ ă€ăłăłăŒăăŹă€ăăă | ïŒŁïœïŒïŒă«ç”ćăăééæäœ |
| CN115175937A (zh) | 2019-12-20 | 2022-10-11 | èŻșćèĄä»œæéć Źćž | çšäșæČ»çéȘšé«çș€ç»ŽććéȘšé«ćąçćŒćžžç»ŒććŸçæTIM-3æäœMBG453ćæTGF-ÎČæäœNIS793äžæäžäžć°è„żä»æ»šææPD-1æäœæŻć·ŽèŸŸç ćæçç»ć |
| PE20230113A1 (es) | 2020-01-16 | 2023-01-27 | Genmab As | Formulaciones de anticuerpos anti-cd38 y usos de las mismas |
| MX2022010515A (es) | 2020-02-28 | 2022-11-14 | Tallac Therapeutics Inc | Conjugacion mediada por transglutaminasa. |
| KR20230005163A (ko) | 2020-03-26 | 2023-01-09 | ìšì ìžíŹ. | ë€ë°ì± êłšììą ìčëŁ ë°©ëČ |
| WO2021207689A2 (en) | 2020-04-10 | 2021-10-14 | Juno Therapeutics, Inc. | Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen |
| US11684676B2 (en) | 2020-05-08 | 2023-06-27 | University Of Southern California | Site-specific antibody-drug conjugates by ADP-ribosyl cyclases |
| EP4150640A1 (en) | 2020-05-13 | 2023-03-22 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
| KR20230024967A (ko) | 2020-06-11 | 2023-02-21 | ë žíë„Ží°ì€ ìêČ | Zbtb32 ì”ì ì ë° ìŽì ì©ë |
| CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| WO2021260186A1 (en) | 2020-06-26 | 2021-12-30 | Juno Therapeutics Gmbh | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| WO2021260657A1 (en) | 2020-06-26 | 2021-12-30 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| US20230303974A1 (en) | 2020-07-30 | 2023-09-28 | Institut Curie | Immune Cells Defective for SOCS1 |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US20230398148A1 (en) | 2020-11-04 | 2023-12-14 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
| US20240018248A1 (en) | 2020-12-02 | 2024-01-18 | Vib Vzw | An ltbr agonist in combination therapy against cancer |
| US20220202859A1 (en) | 2020-12-23 | 2022-06-30 | Crispr Therapeutics Ag | Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor |
| JP2024509853A (ja) | 2021-03-03 | 2024-03-05 | ăžă„ăăŒ ă»ă©ăă„ăŒăăŁăŻăč ă€ăłăłăŒăăŹă€ăăă | 现èçæłăăăłïœïœïœé»ćźłć€ăźç”ćă |
| KR20230157371A (ko) | 2021-03-17 | 2023-11-16 | ë€ìŽìŽì° ì°ìż ê°ë¶ìí€ê°ìŽì€ | íììžížìœëŠ° ìì©ìČŽ ìêž° íìČŽì ëí í€ë©ëŒ ìì©ìČŽë„Œ ìœëíë ì ì ì |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | ç棫ćè«ŸèŻć Źćž | æÎČæé«ćć ¶ä»æČ»çćçšæŒæČ»çćąæźæ§çŸç äčçšé |
| TW202309294A (zh) | 2021-04-27 | 2023-03-01 | ç棫ćè«ŸèŻć Źćž | ç æŻèŒé«ççąçł»ç”± |
| US20250283037A1 (en) | 2021-05-06 | 2025-09-11 | Juno Therapeutics Gmbh | Methods for stimulating and transducing t cells |
| WO2022238386A1 (en) | 2021-05-10 | 2022-11-17 | Institut Curie | Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases |
| US20220387488A1 (en) | 2021-05-12 | 2022-12-08 | Crispr Therapeutics Ag | Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies |
| TW202309077A (zh) | 2021-05-12 | 2023-03-01 | ç棫ćïŒŁïœïœïœïœïœæČ»çć Źćž | çšæŒæČ»ç毊æ§ç€çé¶ćïœïœïŒïŒçćșć ć·„çšćć ç«çŽ°è |
| US20240261446A1 (en) * | 2021-05-17 | 2024-08-08 | Université de LiÚge | Anti-cd38 single domain antibodies in disease monitoring and treatment |
| WO2022248602A1 (en) | 2021-05-25 | 2022-12-01 | Institut Curie | Myeloid cells overexpressing bcl2 |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| KR20240042442A (ko) | 2021-07-28 | 2024-04-02 | ì ëší íŹ, ìžíŹ. | íìĄì ìčëŁë„Œ ìí IL15/IL15R ìí ìŽìą ìŽëìČŽ Fc-ì”í© ëšë°±ì§ |
| US20250135745A1 (en) | 2021-08-13 | 2025-05-01 | 3M Innovative Properties Company | Antistatic fabric article |
| CN113896802A (zh) * | 2021-10-09 | 2022-01-07 | ćźææç§çç©ć»èŻææŻïŒäžæ”·ïŒæéć Źćž | é¶ćcd47ćcd38çéç»èćèçœćć ¶ć¶ć€ćçšé |
| WO2023126458A1 (en) | 2021-12-28 | 2023-07-06 | Mnemo Therapeutics | Immune cells with inactivated suv39h1 and modified tcr |
| US20250101379A1 (en) | 2022-01-28 | 2025-03-27 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
| CA3252736A1 (en) | 2022-02-18 | 2023-08-24 | Rakuten Medical, Inc. | Anti-PD-L1 (Programmed Death-Ligand 1) Antibody Molecules, Coding Polynucleotides, and Methods of Use |
| EP4499677A1 (en) | 2022-03-31 | 2025-02-05 | Institut Curie | Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression |
| US20250297282A1 (en) | 2022-05-05 | 2025-09-25 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
| US20250302954A1 (en) | 2022-05-11 | 2025-10-02 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
| EP4532695A1 (en) | 2022-05-25 | 2025-04-09 | Celgene Corporation | Methods of manufacturing t cell therapies |
| WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
| EP4583913A1 (en) * | 2022-09-09 | 2025-07-16 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies for treating patients with moderate to severe systemic lupus erythematosus |
| TW202423970A (zh) | 2022-10-10 | 2024-06-16 | ç棫ć蔫ććæçŸ èĄä»œć Źćž | ïœïœïœïŒïœ ïœïœïœćïœïœïŒïŒæé«äčç”ćçæł |
| CN120112650A (zh) | 2022-10-26 | 2025-06-06 | èŻșćèĄä»œæéć Źćž | æ ąç æŻé ć¶ć |
| EP4612177A1 (en) | 2022-10-31 | 2025-09-10 | Genmab A/S | Cd38 antibodies and uses thereof |
| EP4615960A1 (en) | 2022-11-09 | 2025-09-17 | C3S2 GmbH | Methods for manufacturing engineered immune cells |
| KR20250121074A (ko) | 2022-12-09 | 2025-08-11 | ìŁŒë ž ìëŹíší°íŹì€ ìžìœíŒë ìŽí°ë | íëĄê·žëíœ ìŽëŻžì§ì ìŹì©íìŹ ìžíŹ íííì ììžĄíêž° ìí êž°êł íì” ë°©ëČ |
| WO2024147934A1 (en) | 2023-01-06 | 2024-07-11 | Takeda Pharmaceutical Company Limited | Anti-cd38 antibodies for the treatment of autoimmune diseases |
| EP4658675A1 (en) | 2023-02-03 | 2025-12-10 | C3S2 GmbH | Methods for non-viral manufacturing of engineered immune cells |
| AU2024276994A1 (en) | 2023-05-24 | 2025-10-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2025042742A1 (en) | 2023-08-18 | 2025-02-27 | Bristol-Myers Squibb Company | Compositions comprising antibodies that bind bcma and cd3 and methods of treatment |
| WO2025153973A1 (en) | 2024-01-16 | 2025-07-24 | MorphoSys GmbH | Highly concentrated liquid formulations for antibodies |
| WO2025193746A1 (en) | 2024-03-12 | 2025-09-18 | Takeda Pharmaceutical Company Limited | Dosing regimens of anti-cd38 antibodies for treatment of subjects with immune thrombocytopenia |
| WO2025235919A1 (en) | 2024-05-09 | 2025-11-13 | Takeda Pharmaceutical Company Limited | Dosing regimens of anti-cd38 antibodies for treatment of subjects with immunoglobulin a nephropathy |
| CN119119277B (zh) * | 2024-10-24 | 2025-09-09 | æ·±ćłææŻć€§ćŠ | äžç§é¶ćcd38ççșłç±łæäœăèŻç©ç»ćç©ćć ¶ćșçš |
Family Cites Families (163)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4169888A (en) | 1977-10-17 | 1979-10-02 | The Upjohn Company | Composition of matter and process |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | ćłăźçŽ æ ȘćŒäŒç€Ÿ | 代çšèĄæ¶Č |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| JPH0684377B2 (ja) | 1986-04-17 | 1994-10-26 | ććéé ”ć·„æ„æ ȘćŒäŒç€Ÿ | æ°èŠććç©ïœïœâïŒïŒïœćăłïœïœâïŒïŒïœïŒ |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| US5053394A (en) | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
| US5084468A (en) | 1988-08-11 | 1992-01-28 | Kyowa Hakko Kogyo Co., Ltd. | Dc-88a derivatives |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP2598116B2 (ja) | 1988-12-28 | 1997-04-09 | ććéé ”ć·„æ„æ ȘćŒäŒç€Ÿ | æ°èŠç©èłȘïœïœïŒïŒïŒ |
| US5187186A (en) | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
| JP2510335B2 (ja) | 1989-07-03 | 1996-06-26 | ććéé ”ć·„æ„æ ȘćŒäŒç€Ÿ | ïœâïŒïŒïœèȘć°äœ |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1991017158A1 (en) | 1990-05-07 | 1991-11-14 | Scripps Clinic And Research Foundation | Intermediates in the formation of the calicheamicin and esperamicin oligosaccharides |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| DK0563475T3 (da) | 1992-03-25 | 2000-09-18 | Immunogen Inc | Konjugater af cellebindende midler og derivater af CC-1065 |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| AU6123894A (en) * | 1993-01-29 | 1994-08-15 | Board Of Trustees Of The Leland Stanford Junior University | Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| WO1995009864A1 (en) | 1993-10-01 | 1995-04-13 | Teikoku Hormone Mfg. Co., Ltd. | Novel peptide derivative |
| ES2220927T3 (es) | 1994-04-22 | 2004-12-16 | Kyowa Hakko Kogyo Co., Ltd. | Derivados de dc-89. |
| JPH07309761A (ja) | 1994-05-20 | 1995-11-28 | Kyowa Hakko Kogyo Co Ltd | ăă„ăȘă«ă«ăă€ă·ăłèȘć°äœăźćźćźćæł |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5550246A (en) | 1994-09-07 | 1996-08-27 | The Scripps Research Institute | Calicheamicin mimics |
| US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| DE69626849T2 (de) | 1995-12-22 | 2003-12-24 | Bristol-Myers Squibb Co., Princeton | Verzweigte hydrazongruppen enthaltende kuppler |
| SI1325932T1 (cg-RX-API-DMAC7.html) * | 1997-04-07 | 2005-08-31 | Genentech Inc | |
| ES2434961T5 (es) | 1998-04-20 | 2018-01-18 | Roche Glycart Ag | IngenierĂa de glicosilaciĂłn de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo |
| US7112661B1 (en) | 1998-10-30 | 2006-09-26 | The Research Foundation Of State University Of New York | Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha |
| US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
| US7303749B1 (en) | 1999-10-01 | 2007-12-04 | Immunogen Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| HK1049787B (en) | 1999-10-01 | 2014-07-25 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| JPWO2002030954A1 (ja) | 2000-10-06 | 2004-02-19 | ććéé ”ć·„æ„æ ȘćŒäŒç€Ÿ | æäœăçČŸèŁœăăæčæł |
| EP3263702A1 (en) | 2000-10-06 | 2018-01-03 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
| IT1320715B1 (it) | 2000-10-19 | 2003-12-10 | Cselt Centro Studi Lab Telecom | Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| ATE374214T1 (de) * | 2001-04-27 | 2007-10-15 | Kirin Brewery | Monoklonaler anti-cd-40-antikörper |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US7087600B2 (en) | 2001-05-31 | 2006-08-08 | Medarex, Inc. | Peptidyl prodrugs and linkers and stabilizers useful therefor |
| IL166244A0 (en) | 2001-07-12 | 2006-01-15 | Jefferson Foote | Super humanized antibodies |
| DE60215819T2 (de) | 2001-08-03 | 2007-09-06 | Tyco Healthcare Group Lp, Norwalk | Marker zur verwendung mit einem gewebemarkierungsgerÀt |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| EP2353611B1 (en) | 2002-07-31 | 2015-05-13 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| US20060235208A1 (en) | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| DE10246870B3 (de) | 2002-10-08 | 2004-04-29 | Renk Aktiengesellschaft | Elektro-Hydrodynamische Ăberlagerungslenkung |
| CN100526460C (zh) * | 2002-11-08 | 2009-08-12 | éșéșć»èŻæ ȘćŒäŒç€Ÿ | æç æŻèçœæŽ»æ§éäœçèœŹćșć æèčç±»ćšç©ćć ¶çšé |
| US7705045B2 (en) | 2002-11-14 | 2010-04-27 | Syntarga, B.V. | Prodrugs built as multiple self-elimination-release spacers |
| WO2006113909A2 (en) | 2005-04-19 | 2006-10-26 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
| CR20170291A (es) | 2003-05-20 | 2017-07-27 | Immunogen Inc | Agentes citotoxicos mejorados que comprenden nuevos maitansinĂłides |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | ìì í ì§ë€í±ì€, ìžíŹ. | 늏ê°ëì ì í©ë ì ìë ëȘšë žë©ížë°ëŠ° íí©ëŹŒ |
| AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| EP1725586B1 (en) | 2004-03-02 | 2015-01-14 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
| JP4806680B2 (ja) | 2004-05-19 | 2011-11-02 | ăĄăăŹăăŻăč ă€ăłăłăŒăăŹă€ăăă | èȘć·±ç çČăȘăłă«ăŒćăłèŹć€è€ćäœ |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | ĐДЎаŃĐ”ĐșŃ, ĐĐœĐș. | Đ„ĐžĐŒĐžŃĐ”ŃĐșОД Đ»ĐžĐœĐșĐ”ŃŃ Đž ĐžŃ ĐșĐŸĐœŃŃгаŃŃ |
| CN101065151B (zh) | 2004-09-23 | 2014-12-10 | ć„æł°ç§çç©ææŻć Źćž | ćè±æ°šé žæčé çæäœćć¶èç© |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| NZ586780A (en) * | 2005-03-23 | 2012-02-24 | Genmab As | Antibodies against CD38 for treatment of multiple myeloma |
| US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| EP2799451A1 (en) * | 2005-05-24 | 2014-11-05 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLDÂź-derived therapeutic antibodies specific for human CD38 |
| PT3248613T (pt) | 2005-07-18 | 2022-03-16 | Seagen Inc | Conjugados de ligante de fĂĄrmaco e beta-glucuronida |
| WO2007018431A2 (en) | 2005-08-05 | 2007-02-15 | Syntarga B.V. | Triazole-containing releasable linkers and conjugates comprising the same |
| DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
| KR20150139636A (ko) * | 2005-10-12 | 2015-12-11 | ëȘšë„ŽíŹìì€ ìêČ | ìžê° ïœïœ38ì íčìŽì ìž ìì ìžê° ïœïœïœïœïœ ïœïœïœïœ-ì ë ìčëŁ íìČŽë€ì ìì± ë° íëĄíìŒë§ |
| EP1940789B1 (en) | 2005-10-26 | 2011-11-23 | Medarex, Inc. | Methods and compounds for preparing cc-1065 analogs |
| CA2627190A1 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| RU2489423C2 (ru) | 2006-02-02 | 2013-08-10 | ĐĄĐžĐœŃĐ°Ńга Đ.Đ. | ĐĐŸĐŽĐŸŃĐ°ŃŃĐČĐŸŃĐžĐŒŃĐ” Đ°ĐœĐ°Đ»ĐŸĐłĐž ŃŃ-1065 Đž ĐžŃ ĐșĐŸĐœŃŃгаŃŃ |
| EP2078732B1 (en) | 2006-07-10 | 2015-09-16 | Fujita Health University | Method of identifying a candidate diagnostic or therapeutic antibody using flow cytometry |
| EP3753576A1 (en) * | 2006-09-26 | 2020-12-23 | Genmab A/S | Combination treatment of cd38-expressing tumors |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| CA2695297C (en) | 2007-08-01 | 2017-03-21 | Syntarga B.V. | Substituted cc-1065 analogs and their conjugates |
| US20090076249A1 (en) | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
| AU2008337100B2 (en) * | 2007-12-17 | 2013-02-28 | Pfizer Limited | Treatment of interstitial cystitis |
| CA2727278A1 (en) | 2008-06-16 | 2010-01-21 | Immunogen, Inc. | Novel synergistic effects |
| MX2011001909A (es) * | 2008-08-20 | 2011-03-21 | Centocor Ortho Biotech Inc | Anticuerpos anti-interleucina-13 modificados, composiciones, metodos y usos. |
| PT2344478T (pt) | 2008-11-03 | 2017-11-28 | Syntarga Bv | AnĂĄlogos de cc-1065 e seus conjugados |
| EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| EP2412808B1 (en) | 2009-03-25 | 2016-09-07 | Tohoku University | Lh-type bispecific antibody |
| US10817851B2 (en) | 2009-12-23 | 2020-10-27 | Aristocrat Technologies Australia Pty Limited | System and method for cashless gaming |
| RS59769B1 (sr) | 2010-06-09 | 2020-02-28 | Genmab As | Antitela protiv humanog cd38 |
| KR101912957B1 (ko) | 2010-09-27 | 2018-10-29 | ëȘšë„ŽíŹìì€ ìêČ | ë€ë°ì± êłšììą ë° nhl ìčëŁë„Œ ìí í-cd38 íìČŽ ë° ë ë 늏ëë§ìŽë ëë 볎넎í ìĄ°ë° |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | ĐĄĐ°ĐœĐŸŃŃ | ĐŃĐŸŃОпŃŃ Đ»ĐžĐœĐœĐ° ĐșĐŸĐŒĐ±ŃĐœĐ°ŃŃŃ, ŃĐŸ ĐŒŃŃŃĐžŃŃ Đ°ĐœŃĐžŃŃĐ»ĐŸ, ŃĐșĐ” ŃпДŃĐžŃŃŃĐœĐŸ ŃĐŸĐ·ĐżŃĐ·ĐœĐ°Ń cd38, Ń Đ±ĐŸŃŃĐ”Đ·ĐŸĐŒŃб |
| GB2486424A (en) | 2010-12-13 | 2012-06-20 | Univ Sussex | Markers for plasma cell disorders |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | ۧÙŰŁŰŹŰłŰ§Ù Ű§ÙÙ Ű¶Ű§ŰŻŰ© ÙÙ cd38 |
| MX353143B (es) | 2011-02-28 | 2017-12-20 | Genentech Inc | Marcadores biologicos y metodos para pronosticar respuesta a antagonistas de celulas b. |
| CN103501825B (zh) | 2011-05-02 | 2017-03-15 | ć ç«ć»çć Źćž | çšäșć°äœç§Żæœçšçćç§ćŒćéæ©çæäœçè¶ æ»€æ”猩 |
| GB201203938D0 (en) | 2012-03-06 | 2012-04-18 | Binding Site Group The Ltd | Assay system |
| GB201212900D0 (en) | 2012-07-20 | 2012-09-05 | Binding Site Group The Ltd | Triage scoring system |
| UA118255C2 (uk) | 2012-12-07 | 2018-12-26 | ĐĄĐ°ĐœĐŸŃŃ | ĐĐŸĐŒĐżĐŸĐ·ĐžŃŃŃ, ŃĐșĐ° ĐŒŃŃŃĐžŃŃ Đ°ĐœŃĐžŃŃĐ»ĐŸ ĐŽĐŸ cd38 Ń Đ»Đ”ĐœĐ°Đ»ŃĐŽĐŸĐŒŃĐŽ |
| US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| US20160075766A1 (en) | 2013-05-21 | 2016-03-17 | Roche Diagnostics Operations, Inc. | Method for producing antibodies using ovine b-cells and uses thereof |
| US10782290B2 (en) | 2013-06-11 | 2020-09-22 | National Center Of Neurology And Psychiatry | Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy |
| EP3027656B1 (en) | 2013-07-30 | 2019-06-26 | SBI Biotech Co., Ltd. | Medicament comprising anti-phospholipase d4 antibody |
| EP3063173B1 (en) | 2013-10-31 | 2020-07-29 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | йДĐČĐ° ЀаŃĐŒĐ°ŃŃŃŃĐžĐșалз ĐŃŃŃĐ”ĐčĐ»ŃĐ° ĐŃŃ ĐŃĐŽ | ĐĐŸĐŒĐ±ŃĐœĐ°ŃŃŃ Đ»Đ”ĐœĐ°Đ»ŃĐŽĐŸĐŒŃĐŽŃ Đ°Đ±ĐŸ ĐżĐŸĐŒĐ°Đ»ŃĐŽĐŸĐŒŃĐŽŃ Ń ĐșĐŸĐœŃŃŃŃĐșŃŃŃ Đ°ĐœŃĐž-cd38 Đ°ĐœŃĐžŃŃĐ»ĐŸ-Đ°ŃĐ”ĐœŃĐčĐŸĐČĐ°ĐœĐžĐč ŃĐœŃĐ”ŃŃĐ”ŃĐŸĐœ Đ°Đ»ŃŃĐ°-2b ŃĐ° ŃĐżĐŸŃŃб Đ»ŃĐșŃĐČĐ°ĐœĐœŃ ŃŃб'ŃĐșŃĐ°, ŃĐșĐžĐč ĐŒĐ°Ń cd38-Đ”ĐșŃĐżŃĐ”ŃŃŃŃŃ ĐżŃŃ Đ»ĐžĐœŃ |
| US10617757B2 (en) | 2014-08-08 | 2020-04-14 | The Regents Of The University Of California | Methods for treating multiple myeloma |
| PH12017500442B1 (en) | 2014-09-09 | 2023-05-24 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
| MA41555A (fr) | 2015-02-17 | 2017-12-26 | Millennium Pharm Inc | Polythérapie pour le traitement du cancer |
| PT3294769T (pt) | 2015-05-13 | 2021-04-13 | Morphosys Ag | Tratamento para mieloma mĂșltiplo (mm) |
| CN108136218B (zh) | 2015-05-20 | 2022-12-13 | è©čæŁźçç©ç§æć Źćž | çšäșæČ»ç蜻éŸæ·çČæ ·ćæ§ćć ¶ćźcd38éłæ§èĄæ¶Čæ¶æ§èżç€çæcd38æäœ |
| HUE053366T2 (hu) | 2015-11-03 | 2021-06-28 | Janssen Biotech Inc | SzubkutĂĄn anti-CD38-ellenanyag-kĂ©szĂtmĂ©nyek Ă©s alkalmazĂĄsuk |
| US20170121417A1 (en) | 2015-11-03 | 2017-05-04 | Janssen Biotech, Inc. | Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses |
| US11613586B2 (en) * | 2016-07-15 | 2023-03-28 | Takeda Pharmaceutical Company Limited | Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies |
| US20180117150A1 (en) | 2016-11-01 | 2018-05-03 | Janssen Biotech, Inc. | Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide |
| US11392902B2 (en) | 2017-06-06 | 2022-07-19 | United Parcel Service Of America, Inc. | Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery |
| CN111565751A (zh) | 2017-10-31 | 2020-08-21 | è©čæŁźçç©ç§æć Źćž | æČ»çé«ć±ć€ćæ§éȘšé«ç€çæčæł |
| WO2019140410A1 (en) * | 2018-01-12 | 2019-07-18 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-cd38 antibodies |
| MX2021000307A (es) * | 2018-07-11 | 2021-09-08 | Momenta Pharmaceuticals Inc | Composiciones y mĂ©todos relacionados con constructos de dominio de uniĂłn a antĂgeno-fc dirigidos a cd38 diseñados por ingenierĂa genĂ©tica. |
-
2010
- 2010-12-30 JO JOP/2021/0044A patent/JOP20210044A1/ar unknown
-
2011
- 2011-12-29 AR ARP110105024A patent/AR084747A1/es active IP Right Grant
- 2011-12-29 TW TW100149611A patent/TWI564304B/zh active
- 2011-12-29 JO JOP/2011/0402A patent/JOP20110402B1/ar active
- 2011-12-30 PE PE2013001487A patent/PE20140247A1/es active IP Right Grant
- 2011-12-30 SI SI201131534T patent/SI2658870T1/sl unknown
- 2011-12-30 PT PT171899255T patent/PT3284754T/pt unknown
- 2011-12-30 PT PT118107770T patent/PT2658870T/pt unknown
- 2011-12-30 JP JP2013547710A patent/JP5843884B2/ja active Active
- 2011-12-30 AU AU2011351921A patent/AU2011351921B2/en active Active
- 2011-12-30 EP EP17189925.5A patent/EP3284754B1/en active Active
- 2011-12-30 DK DK11810777.0T patent/DK2658870T3/en active
- 2011-12-30 DK DK11811633.4T patent/DK2658871T3/en active
- 2011-12-30 CN CN202110630414.2A patent/CN113480649B/zh active Active
- 2011-12-30 DK DK17189925.5T patent/DK3284754T3/da active
- 2011-12-30 KR KR1020207001665A patent/KR102294213B1/ko active Active
- 2011-12-30 PL PL17189925T patent/PL3284754T3/pl unknown
- 2011-12-30 UY UY0001033850A patent/UY33850A/es not_active Application Discontinuation
- 2011-12-30 SG SG2013046651A patent/SG191211A1/en unknown
- 2011-12-30 RS RS20201556A patent/RS61280B1/sr unknown
- 2011-12-30 LT LTEP11811633.4T patent/LT2658871T/lt unknown
- 2011-12-30 CN CN202510038185.3A patent/CN119775422A/zh active Pending
- 2011-12-30 SI SI201131939T patent/SI3284754T1/sl unknown
- 2011-12-30 KR KR1020137017570A patent/KR101945002B1/ko active Active
- 2011-12-30 NZ NZ705848A patent/NZ705848A/en unknown
- 2011-12-30 KR KR1020217026369A patent/KR102451597B1/ko active Active
- 2011-12-30 US US13/977,207 patent/US9102744B2/en active Active
- 2011-12-30 EP EP20189000.1A patent/EP3798231A1/en not_active Withdrawn
- 2011-12-30 HU HUE11811633A patent/HUE038727T2/hu unknown
- 2011-12-30 HR HRP20181245TT patent/HRP20181245T1/hr unknown
- 2011-12-30 KR KR1020227034240A patent/KR102602640B1/ko active Active
- 2011-12-30 HR HRP20181176TT patent/HRP20181176T1/hr unknown
- 2011-12-30 JP JP2013547713A patent/JP6148984B2/ja active Active
- 2011-12-30 CN CN201710699217.XA patent/CN107365385A/zh active Pending
- 2011-12-30 EA EA201390993A patent/EA029303B1/ru unknown
- 2011-12-30 WO PCT/US2011/068235 patent/WO2012092612A1/en not_active Ceased
- 2011-12-30 KR KR1020197002704A patent/KR102070326B1/ko active Active
- 2011-12-30 SI SI201131541T patent/SI2658871T1/sl unknown
- 2011-12-30 HU HUE11810777A patent/HUE038535T2/hu unknown
- 2011-12-30 CN CN201180063232.6A patent/CN103282383B/zh active Active
- 2011-12-30 EA EA201791186A patent/EA201791186A1/ru unknown
- 2011-12-30 MX MX2013007455A patent/MX350903B/es active IP Right Grant
- 2011-12-30 EP EP20198444.0A patent/EP3789404A1/en active Pending
- 2011-12-30 US US13/341,860 patent/US8362211B2/en active Active
- 2011-12-30 ES ES11810777.0T patent/ES2674175T3/es active Active
- 2011-12-30 EP EP11811633.4A patent/EP2658871B1/en active Active
- 2011-12-30 EP EP17189927.1A patent/EP3284755B1/en active Active
- 2011-12-30 HU HUE17189925A patent/HUE052906T2/hu unknown
- 2011-12-30 SM SM20180388T patent/SMT201800388T1/it unknown
- 2011-12-30 PL PL11811633T patent/PL2658871T3/pl unknown
- 2011-12-30 PL PL11810777T patent/PL2658870T3/pl unknown
- 2011-12-30 LT LTEP17189925.5T patent/LT3284754T/lt unknown
- 2011-12-30 SM SM20180405T patent/SMT201800405T1/it unknown
- 2011-12-30 PT PT118116334T patent/PT2658871T/pt unknown
- 2011-12-30 EP EP11810777.0A patent/EP2658870B1/en active Active
- 2011-12-30 CA CA2822061A patent/CA2822061C/en active Active
- 2011-12-30 GE GEAP201113177A patent/GEP20166493B/en unknown
- 2011-12-30 LT LTEP11810777.0T patent/LT2658870T/lt unknown
- 2011-12-30 RS RS20180859A patent/RS57526B1/sr unknown
- 2011-12-30 WO PCT/US2011/068244 patent/WO2012092616A1/en not_active Ceased
- 2011-12-30 NZ NZ61227211A patent/NZ612272A/en unknown
- 2011-12-30 RS RS20180902A patent/RS57494B1/sr unknown
- 2011-12-30 ES ES17189925T patent/ES2841299T3/es active Active
- 2011-12-30 ES ES11811633.4T patent/ES2690095T3/es active Active
- 2011-12-30 BR BR112013017009-3A patent/BR112013017009B1/pt active IP Right Grant
- 2011-12-30 MY MYPI2013002489A patent/MY160499A/en unknown
-
2012
- 2012-12-19 US US13/720,837 patent/US8926969B2/en active Active
- 2012-12-30 TR TR2018/08709T patent/TR201808709T4/tr unknown
-
2013
- 2013-06-16 IL IL226973A patent/IL226973A/en active IP Right Grant
- 2013-06-21 CR CR20130313A patent/CR20130313A/es unknown
- 2013-06-24 ZA ZA2013/04696A patent/ZA201304696B/en unknown
- 2013-06-25 MX MX2020012426A patent/MX2020012426A/es unknown
- 2013-06-27 MA MA36052A patent/MA34763B1/fr unknown
- 2013-07-18 CO CO13170417A patent/CO6761368A2/es active IP Right Grant
- 2013-07-29 EC ECSP13012794 patent/ECSP13012794A/es unknown
-
2014
- 2014-11-21 US US14/550,796 patent/US9790285B2/en active Active
-
2015
- 2015-06-29 US US14/754,592 patent/US9676869B2/en active Active
- 2015-09-02 JP JP2015172783A patent/JP6425635B2/ja active Active
- 2015-12-18 JP JP2015247967A patent/JP6425644B2/ja active Active
-
2017
- 2017-05-17 US US15/598,241 patent/US10336833B2/en active Active
- 2017-07-04 AU AU2017204571A patent/AU2017204571B2/en active Active
- 2017-07-24 JP JP2017143106A patent/JP6621447B2/ja active Active
- 2017-07-24 JP JP2017143107A patent/JP6563446B2/ja active Active
- 2017-09-13 US US15/703,833 patent/US10494444B2/en active Active
-
2018
- 2018-07-24 CY CY20181100773T patent/CY1122161T1/el unknown
- 2018-08-02 CY CY20181100806T patent/CY1122165T1/el unknown
-
2019
- 2019-05-14 US US16/412,297 patent/US20200031951A1/en not_active Abandoned
- 2019-07-24 JP JP2019136165A patent/JP6766233B2/ja active Active
- 2019-09-25 JP JP2019174782A patent/JP6840813B2/ja active Active
- 2019-10-17 US US16/656,401 patent/US11434304B2/en active Active
- 2019-11-13 AU AU2019264573A patent/AU2019264573B2/en active Active
-
2020
- 2020-09-16 JP JP2020155609A patent/JP7096301B2/ja active Active
- 2020-12-14 HR HRP20201996TT patent/HRP20201996T1/hr unknown
- 2020-12-21 CY CY20201101205T patent/CY1123739T1/el unknown
-
2021
- 2021-02-17 JP JP2021023741A patent/JP7315598B2/ja active Active
-
2022
- 2022-08-31 US US17/823,905 patent/US12209138B2/en active Active
-
2024
- 2024-12-18 US US18/986,517 patent/US20250171561A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201304696B (en) | Anti-cd38 antibodies | |
| AP4082A (en) | Anti-cd40 antibodies | |
| ZA201209004B (en) | Anti-fgfr2 antibodies | |
| GB201000467D0 (en) | Antibodies | |
| IL221371A0 (en) | Anti-lrp6 antibodies | |
| PL2581113T3 (pl) | PrzeciwciaĆo anty-tim-3 | |
| HUE038962T2 (hu) | DLL3-ellenes antitest | |
| PL2616489T3 (pl) | PrzeciwciaĆo anty-huTNFR1 | |
| PT2603528T (pt) | Anticorpos glicosilados em fab | |
| GB201020738D0 (en) | Antibodies | |
| ZA201302459B (en) | Antibodies | |
| GB201002238D0 (en) | Antibodies | |
| GB201007957D0 (en) | Antibody | |
| PH12013501424A1 (en) | Anti-cd38 antibodies | |
| GB201020751D0 (en) | Antibodies | |
| GB201005062D0 (en) | Antibodies | |
| GB201017780D0 (en) | Antibody |